IL315895A - Postpartum depression treatment - Google Patents
Postpartum depression treatmentInfo
- Publication number
- IL315895A IL315895A IL315895A IL31589524A IL315895A IL 315895 A IL315895 A IL 315895A IL 315895 A IL315895 A IL 315895A IL 31589524 A IL31589524 A IL 31589524A IL 315895 A IL315895 A IL 315895A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- postnatal depression
- postnatal
- depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22000085 | 2022-03-27 | ||
| EP22000084 | 2022-03-27 | ||
| EP23153996 | 2023-01-30 | ||
| EP23154014 | 2023-01-30 | ||
| PCT/EP2023/057885 WO2023186837A1 (en) | 2022-03-27 | 2023-03-27 | Treatment of postnatal depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315895A true IL315895A (en) | 2024-11-01 |
Family
ID=86007029
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315895A IL315895A (en) | 2022-03-27 | 2023-03-27 | Postpartum depression treatment |
| IL315903A IL315903A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of cognitive dysfunction |
| IL315904A IL315904A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of social/emotional withdrawal or withdrawal |
| IL315901A IL315901A (en) | 2022-03-27 | 2023-03-27 | 5-MEO-DMT for use in the treatment of sleep disorders |
| IL315905A IL315905A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N.N-DIMETHYLTRYPTamine for the treatment of psychomotor retardation |
| IL315900A IL315900A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of anxiety |
| IL315892A IL315892A (en) | 2022-03-27 | 2023-03-27 | 5-MEO-DTM for the treatment of bipolar disorder |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315903A IL315903A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of cognitive dysfunction |
| IL315904A IL315904A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of social/emotional withdrawal or withdrawal |
| IL315901A IL315901A (en) | 2022-03-27 | 2023-03-27 | 5-MEO-DMT for use in the treatment of sleep disorders |
| IL315905A IL315905A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N.N-DIMETHYLTRYPTamine for the treatment of psychomotor retardation |
| IL315900A IL315900A (en) | 2022-03-27 | 2023-03-27 | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of anxiety |
| IL315892A IL315892A (en) | 2022-03-27 | 2023-03-27 | 5-MEO-DTM for the treatment of bipolar disorder |
Country Status (9)
| Country | Link |
|---|---|
| US (10) | US20250235427A1 (enExample) |
| EP (8) | EP4499085A1 (enExample) |
| JP (7) | JP2025510294A (enExample) |
| KR (7) | KR20250005182A (enExample) |
| CN (5) | CN119546298A (enExample) |
| AU (7) | AU2023244447A1 (enExample) |
| CA (7) | CA3255652A1 (enExample) |
| IL (7) | IL315895A (enExample) |
| WO (9) | WO2023186832A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| EP3868364A1 (en) | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| EP4277894A1 (en) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026078143A1 (en) | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200147038A1 (en) * | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| HUE066828T2 (hu) | 2019-02-22 | 2024-09-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére |
| DK3927338T3 (da) * | 2019-02-22 | 2025-01-06 | Gh Res Ireland Limited | Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser |
| KR20220008824A (ko) * | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| US20230157981A1 (en) * | 2020-04-20 | 2023-05-25 | Lobe Sciences Ltd. | Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder |
| BR112022025306A2 (pt) * | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| US11406619B2 (en) * | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| WO2022189662A1 (en) * | 2021-03-12 | 2022-09-15 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
| CA3216889A1 (en) * | 2021-04-26 | 2022-11-03 | Glenn Short | Novel n,n-dimethyltryptamine compositions and methods |
| WO2023028086A1 (en) * | 2021-08-23 | 2023-03-02 | Gilgamesh Pharmaceuticals, Inc. | Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonists |
| AU2022413759A1 (en) * | 2021-12-13 | 2024-06-27 | Beckley Psytech Limited | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
-
2023
- 2023-03-27 KR KR1020247035759A patent/KR20250005182A/ko active Pending
- 2023-03-27 US US18/851,301 patent/US20250235427A1/en active Pending
- 2023-03-27 KR KR1020247035654A patent/KR20240167878A/ko active Pending
- 2023-03-27 WO PCT/EP2023/057879 patent/WO2023186832A1/en not_active Ceased
- 2023-03-27 CA CA3255652A patent/CA3255652A1/en active Pending
- 2023-03-27 US US18/851,316 patent/US20250213530A1/en not_active Abandoned
- 2023-03-27 WO PCT/EP2023/057828 patent/WO2023186798A1/en not_active Ceased
- 2023-03-27 JP JP2024557206A patent/JP2025510294A/ja active Pending
- 2023-03-27 IL IL315895A patent/IL315895A/en unknown
- 2023-03-27 IL IL315903A patent/IL315903A/en unknown
- 2023-03-27 CA CA3255338A patent/CA3255338A1/en active Pending
- 2023-03-27 EP EP23717045.1A patent/EP4499085A1/en active Pending
- 2023-03-27 US US18/851,362 patent/US20250213534A1/en active Pending
- 2023-03-27 EP EP23717044.4A patent/EP4499084A1/en active Pending
- 2023-03-27 US US18/851,329 patent/US20250170099A1/en active Pending
- 2023-03-27 JP JP2024557207A patent/JP2025510295A/ja active Pending
- 2023-03-27 IL IL315904A patent/IL315904A/en unknown
- 2023-03-27 CA CA3255654A patent/CA3255654A1/en active Pending
- 2023-03-27 CN CN202380036934.8A patent/CN119546298A/zh active Pending
- 2023-03-27 AU AU2023244447A patent/AU2023244447A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057875 patent/WO2023186828A1/en not_active Ceased
- 2023-03-27 US US18/851,294 patent/US20250213528A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057874 patent/WO2023186827A1/en not_active Ceased
- 2023-03-27 CN CN202380042750.2A patent/CN119255799A/zh active Pending
- 2023-03-27 JP JP2024557197A patent/JP2025510913A/ja active Pending
- 2023-03-27 CN CN202380042391.0A patent/CN119255798A/zh active Pending
- 2023-03-27 US US18/851,311 patent/US20250213529A1/en active Pending
- 2023-03-27 JP JP2024557761A patent/JP2025511084A/ja active Pending
- 2023-03-27 WO PCT/EP2023/057885 patent/WO2023186837A1/en not_active Ceased
- 2023-03-27 JP JP2024557199A patent/JP2025510914A/ja active Pending
- 2023-03-27 EP EP23717041.0A patent/EP4499081A1/en not_active Withdrawn
- 2023-03-27 AU AU2023246681A patent/AU2023246681A1/en active Pending
- 2023-03-27 KR KR1020247035763A patent/KR20250005184A/ko active Pending
- 2023-03-27 JP JP2024557208A patent/JP2025510296A/ja active Pending
- 2023-03-27 AU AU2023244449A patent/AU2023244449A1/en active Pending
- 2023-03-27 US US18/851,336 patent/US20250213531A1/en active Pending
- 2023-03-27 AU AU2023246548A patent/AU2023246548A1/en active Pending
- 2023-03-27 CA CA3255329A patent/CA3255329A1/en active Pending
- 2023-03-27 IL IL315901A patent/IL315901A/en unknown
- 2023-03-27 IL IL315905A patent/IL315905A/en unknown
- 2023-03-27 KR KR1020247035657A patent/KR20250005173A/ko active Pending
- 2023-03-27 IL IL315900A patent/IL315900A/en unknown
- 2023-03-27 AU AU2023242439A patent/AU2023242439A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057868 patent/WO2023186821A1/en not_active Ceased
- 2023-03-27 KR KR1020247035707A patent/KR20250005175A/ko active Pending
- 2023-03-27 EP EP23717032.9A patent/EP4499072A1/en active Pending
- 2023-03-27 US US18/851,349 patent/US20250213533A1/en active Pending
- 2023-03-27 CN CN202380037532.XA patent/CN119278036A/zh active Pending
- 2023-03-27 EP EP23717034.5A patent/EP4499074A1/en active Pending
- 2023-03-27 EP EP23717038.6A patent/EP4499078A1/en active Pending
- 2023-03-27 KR KR1020247035719A patent/KR20250005177A/ko active Pending
- 2023-03-27 CA CA3255511A patent/CA3255511A1/en active Pending
- 2023-03-27 JP JP2024557757A patent/JP2025512866A/ja active Pending
- 2023-03-27 CN CN202380035882.2A patent/CN119156212A/zh active Pending
- 2023-03-27 EP EP23717413.1A patent/EP4499089A1/en active Pending
- 2023-03-27 CA CA3255640A patent/CA3255640A1/en active Pending
- 2023-03-27 CA CA3255709A patent/CA3255709A1/en active Pending
- 2023-03-27 EP EP23717037.8A patent/EP4499077A1/en not_active Withdrawn
- 2023-03-27 AU AU2023246773A patent/AU2023246773A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057871 patent/WO2023186824A1/en not_active Ceased
- 2023-03-27 KR KR1020247035720A patent/KR20250005178A/ko active Pending
- 2023-03-27 IL IL315892A patent/IL315892A/en unknown
- 2023-03-27 WO PCT/EP2023/057878 patent/WO2023186831A1/en not_active Ceased
- 2023-03-27 WO PCT/EP2023/057845 patent/WO2023186808A1/en not_active Ceased
- 2023-03-27 AU AU2023244453A patent/AU2023244453A1/en active Pending
- 2023-09-27 US US18/373,904 patent/US20240115549A1/en active Pending
- 2023-09-27 US US18/373,914 patent/US20240115550A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4525871A4 (en) | TREATMENT OF DEPRESSION | |
| ZA202206163B (en) | Methods of treating coronavirus | |
| IL320805B1 (en) | Therapeutic uses of tirzepatide | |
| IL308221A (en) | Preparations and methods for treating depression | |
| IL315503A (en) | Treatment methods | |
| RS67100B1 (sr) | Lečenje hiperinflamatornog sindroma | |
| IL291146A (en) | Treatment of hidradenitis with jak inhibitors | |
| IL310725A (en) | Treatment of muscular dystrophy | |
| IL320711A (en) | Treatment methods | |
| IL312583A (en) | A preparation for the treatment and prevention of COVID-19 | |
| GB202411655D0 (en) | Application of circHIF1a | |
| GB2618915B (en) | Treatment of cardiovascular disease | |
| GB202201824D0 (en) | Methods of treatment | |
| EP4591861A4 (en) | USE OF 4-TMAP TO TREAT OR RELIEF FROM DEPRESSION | |
| GB202201825D0 (en) | Methods of treatment | |
| GB202201819D0 (en) | Methods of treatment | |
| IL308377A (en) | Methods for treating skin and muscle inflammation | |
| GB202315695D0 (en) | TReatment of cariomyopathy | |
| GB202212506D0 (en) | Treatment of covid-19 | |
| GB202014412D0 (en) | Treatment of coronavirus | |
| IL325944A (en) | Methods of treatment | |
| GB202307686D0 (en) | Treatment of conditions | |
| GB202316026D0 (en) | Methods of prevention or treatment | |
| GB202101251D0 (en) | Treatment of conditions | |
| GB202118006D0 (en) | Methods of treatment |